Home cancer care breakthrough? new trial lets myeloma patients Self-Inject

NCT ID NCT06015542

Recruiting now Disease control Sponsor: Thomas Lund Source: ClinicalTrials.gov ↗

First seen Feb 20, 2026 · Last updated May 08, 2026 · Updated 16 times

Summary

This study looks at whether people with relapsed multiple myeloma can safely give themselves the drug elranatamab at home instead of going to a clinic. About 20 participants will be trained to self-inject and will track side effects, time spent, and any unplanned hospital visits. The goal is to see if home treatment is safe, practical, and improves quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Heamatology
RECRUITING

Vejle, 7100, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Odense University Hospital
RECRUITING

Odense, 5000, Denmark

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA